Dermatology Times, January 2024 (Vol. 45. No. 01)

Learn more about the in-depth topics covered in the January 2024 print issue of Dermatology Times.

A patient's social media post has gone viral and has been seen by thousands. Dr Derm is concerned this malicious act may ruin his career. What can he do?

This article delves into 5 critical areas that dermatologists should focus on for a comprehensive 2024 report card.

In a recent Dermatology Times Case-Based Roundtable Meeting, Tina Bhutani, MD, MAS, shared intriguing cases and insights about atopic dermatitis treatment challenges faced by patients with different lifestyles and hobbies.

In this month’s Cosmetic Conundrums article, Zoe Diana Draelos, MD, reviews 5 popular social media dermatology trends for dermatology clinicians to be aware of.

This article will highlight recently approved psoriasis therapies that will shape the 2024 treatment landscape and provide some exciting updates in the psoriasis management market this coming year and beyond.

Placental tissues provide a promising alternative for addressing cutaneous reconstruction while maintaining the most cosmetically pleasing outcome.

This article will discuss insights from research studies and offer specialized guidance aimed at dermatologists in hopes of fostering patient adherence in acne management.

Innovative practice pearls for both vitiligo and atopic dermatitis treatment were shared with nearly 200 clinicians to put into practice at the virtual Revolutionizing Vitiligo and Revolutionizing Atopic Dermatitis Conferences.

Winter Editor in Chief Christopher Bunick, MD, PhD, looks ahead to a year of dermatology innovations with a reflection on meaningful advances from 2023.

Dermatology Times is excited to ring in 2024 with a fresh perspective to amplify our impact, foster creativity, and deliver even more exceptional, compelling content to you—our cherished audience.

This CME credit opportunity delves into the pathogenesis and management of hidradenitis suppurativa.

Lisa Swanson, MD, FAAD, and Robert Casquejo, PA-C, discuss their preferred treatment approach for plaque psoriasis, which includes PDE4 inhibitors such as apremilast and roflumilast.

This week’s collection of the latest dermatologic studies covers skin cancer risk associated with phototherapy excluding psoralens, the role of the mycobiome in the development of atopic diseases, underrecognized pediatric vulvar diseases, and sunscreen deserts in Northeast, Ohio.

This week’s collection of the latest dermatologic studies covers the burden of pediatric AD, skin cancer risk associated with combined methotrexate and NB-UVB therapy in patients with moderate to severe PsO, stigma towards patients with acne, and detection of nonmelanoma skin cancers in Mohs surgical sections using deep learning.

The approval of Galderma’s Restylane Eyelight was one of Martin’s top highlights of 2023.